Message #10 From:
NewsBot Date: October 25, 2005 08:20:00 AM
PBME News Webcast Alert: Pacific Biometrics, Inc. Presentation at The PIPEs Conference 2005 to be Webcast on Wednesday, October 26, 9:30am EST
SEATTLE--(BUSINESS WIRE)--Oct. 25, 2005--Pacific Biometrics, Inc. (OTCBB: PBME) will webcast the presentation on October 26th at 9:30am EST at The PIPEs Conference held in New York City at The Waldorf Astoria. To access the presentation, visit the following webcast link: www.vcall.com/CEPage.asp?ID=96259. A webcast will be available on the company's website for 90 days following the conference at www.pacbio.com.
Pacific Biometrics will present on Wednesday, October 26th at 9:30am and 12:30pm and on Thursday, October 27th at 9:30am. The PIPEs Conference 2005 features investors, investment bankers, attorneys, company executives, and industry analysts active in the small cap equity market. The conference includes CLE-accredited workshops, roundtables, and presentations from leading industry professionals. Information about the event can be found at www.thepipesconference.com.
Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, and through its non-profit affiliate Pacific Biometrics Research Foundation, is one of only three U.S.-based members of the Centers for Disease Control (CDC) Cholesterol Reference Method Laboratory Network. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies.
Pacific Biometrics also owns several patented and patent-pending technologies, including monitoring devices for glucose and changes in bone turnover, an advanced, proprietary, isothermal DNA amplification technology, and a gene-based cell viability technology to distinguish live from dead cells in a broad range of diagnostic applications.
For more information about Pacific Biometrics, visit the company's web site at www.pacbio.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release includes forward-looking statements including to but not limited to our strategic planning and business development plans, our future growth, and the viability and acceptance of our products and services in the market. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, our ability to bid on and win laboratory services contracts, the success of our marketing and business development efforts, competition in the industry, and our ability to manage growth and our investments in our infrastructure, as well as the risks and other factors set forth in our periodic filings with the U.S. Securities and Exchange Commission (including our Form 10-KSB for the year end).
